特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
358694

カルシトニン遺伝子関連ペプチド (CGRP):パイプライン製品の分析

Calcitonin Gene Related Peptide - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 96 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
カルシトニン遺伝子関連ペプチド (CGRP):パイプライン製品の分析
出版日: 2020年09月30日
発行: Global Markets Direct
ページ情報: 英文 96 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界各国でのカルシトニン遺伝子関連ペプチド (CGRP) 治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

  • イントロダクション
    • 分析範囲
  • カルシトニン遺伝子関連ペプチド (CGRP) の概要
  • 治療薬の開発
    • 治験中の製品:治験の段階別
    • 治験中の製品:治療領域別
    • 治験中の製品:症状別
  • パイプライン製品の概略
    • 後期段階の製品
    • 初期段階の製品
  • 各企業で開発中の製品
  • 治療薬の評価
    • 単剤治療薬/併用治療薬の場合
    • 作用機序別
    • 投薬経路別
    • 分子の種類別
  • CGRP治療薬の開発に従事している企業
    • Alder Biopharmaceuticals Inc.
    • BCN Peptides, S.A.
    • Boehringer Ingelheim GmbH
    • Eli Lilly and Company
    • BCN Peptides, S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Noxxon Pharma AG
  • 薬剤のプロファイル
    • ALD-403
      • 製品概略
      • 作用機序
      • 研究開発 (R&D) の進行状況
    • DD-04107
    • galcanezumab
    • NOXL-41
    • オルセゲパント
    • 片頭痛・骨関節炎痛向けCGRP阻害用小分子
    • TEV-48125
  • 開発休止状態のプロジェクト
  • 開発が中断されたプロジェクト
  • 注目すべき最新動向・プレスリリース (全10件)
  • 付録

図表一覧

図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..3), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Actavalon Inc, H2 2020
  • Pipeline by Active Biotech AB, H2 2020
  • Pipeline by Ampio Pharmaceuticals Inc, H2 2020
  • Pipeline by AnTolRx Inc, H2 2020
  • Pipeline by Bayer AG, H2 2020
  • Pipeline by Dermavant Sciences Inc, H2 2020
  • Pipeline by Hercules Pharmaceuticals BV, H2 2020
  • Pipeline by Hutchison MediPharma Ltd, H2 2020
  • Pipeline by Ikena Oncology Inc, H2 2020
  • Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020
  • Pipeline by Magenta Therapeutics Inc, H2 2020
  • Pipeline by Pfizer Inc, H2 2020
  • Pipeline by Phenex Pharmaceuticals AG, H2 2020
  • Pipeline by Shenogen Pharma Group Ltd, H2 2020
  • Pipeline by Sol-Gel Technologies Ltd, H2 2020
  • Pipeline by Welichem Biotech Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC2633TDB

Summary:

According to the recently published report 'Calcitonin Gene Related Peptide - Pipeline Review, H2 2020'; Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception.

The report 'Calcitonin Gene Related Peptide - Pipeline Review, H2 2020' outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Preclinical and Discovery stages are 3, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology and Oncology which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Fibromyalgia (Fibromyalgia Syndrome), Inflammatory Pain, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Medullary Thyroid Cancer, Osteoarthritis Pain, Pain, Psoriasis and Traumatic Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
  • The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Calcitonin Gene Related Peptide (CGRP) - Overview
  • Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
  • AfaSci Inc
  • Aptarion biotech AG
  • Eli Lilly and Co
  • H. Lundbeck AS
  • Kissei Pharmaceutical Co Ltd
  • Living Cell Technologies Ltd
  • Nepsone ehf
  • Pharmnovo AB
  • Serometrix LLC
  • Teva Pharmaceutical Industries Ltd
  • United Neuroscience Ltd
  • Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
  • AFAP-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • eptinezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fremanezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • galcanezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Inhibit CGRP for Medullary Thyroid Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KCZ-1279 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LC-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NOXL-41 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CGRP for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CGRP for Psoriasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • UB-313 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Calcitonin Gene Related Peptide (CGRP) - Dormant Products
  • Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
  • Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.